Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Reiss

Showing results (171-180 of 207) with videos related to

Pageof 21
Sort By:
HIV Medicine|January 22, 2011
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*)K Petoumenos, S Worm, P Reiss, et al.
AIDS (London, England)|January 12, 2001
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infectionM den Brinker, F W Wit, P M Wertheim-van Dillen, et al.
American Journal of Clinical Oncology|October 5, 2001
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinomaH Safran, M Steinhoff, S Mangray, et al.
AIDS (London, England)|October 28, 1997
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitisA C Leenders, P Reiss, P Portegies, et al.
Nature Communications|May 17, 2020
HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseasesI Vujkovic-Cvijin, O Sortino, E Verheij, et al.
HIV Medicine|July 19, 2018
Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) studyC I Hatleberg, L Ryom, A d'Arminio Monforte, et al.
The Journal of Infectious Diseases|March 9, 1999
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected personsF W Wit, R van Leeuwen, G J Weverling, et al.
Neurology|August 28, 2002
Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophyA J van der Kooi, G Bonne, B Eymard, et al.
The Journal of Infectious Diseases|January 7, 2012
Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic strokeS W Worm, D A Kamara, P Reiss, et al.
HIV Medicine|January 22, 2003
Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) studyM Law, N Friis-Møller, R Weber, et al.
Pageof 21

Showing results (171-180 of 207) with videos related to

Sort By:
Pageof 21
HIV Medicine|January 22, 2011
Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*)K Petoumenos, S Worm, P Reiss, et al.
AIDS (London, England)|January 12, 2001
Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infectionM den Brinker, F W Wit, P M Wertheim-van Dillen, et al.
American Journal of Clinical Oncology|October 5, 2001
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinomaH Safran, M Steinhoff, S Mangray, et al.
AIDS (London, England)|October 28, 1997
Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitisA C Leenders, P Reiss, P Portegies, et al.
Nature Communications|May 17, 2020
HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseasesI Vujkovic-Cvijin, O Sortino, E Verheij, et al.
HIV Medicine|July 19, 2018
Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV-positive persons: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) studyC I Hatleberg, L Ryom, A d'Arminio Monforte, et al.
The Journal of Infectious Diseases|March 9, 1999
Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected personsF W Wit, R van Leeuwen, G J Weverling, et al.
Neurology|August 28, 2002
Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophyA J van der Kooi, G Bonne, B Eymard, et al.
The Journal of Infectious Diseases|January 7, 2012
Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic strokeS W Worm, D A Kamara, P Reiss, et al.
HIV Medicine|January 22, 2003
Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) studyM Law, N Friis-Møller, R Weber, et al.
Pageof 21